Major Depressive Disorder Market

DelveInsight’s ‘Major Depressive Disorder (MDD) – Market Insights, Epidemiology, and Market Forecast – 2032’ report deliver an in-depth understanding of the historical and forecasted epidemiology as well as the market trends of major depressive disorder (MDD) in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

 

The major depressive disorder (MDD) market report provides current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted major depressive disorder (MDD) market size from 2019 to 2032, segmented by seven major markets. The report also covers the current major depressive disorder (MDD) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying market potential.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2019–2032

Major Depressive Disorder (MDD): Disease Understanding and Treatment Algorithm

Major Depressive Disorder (MDD) Overview

Major depressive disorder (MDD), also referred to as depression, is a serious medical illness that disrupts a person’s mood, behavior, and thought processes, apart from degrading physical health. It should not be mistaken for the passing feelings of unhappiness that everyone experiences, nor should it be confused with the intense grief brought about by the death of a loved one. Sadness and grief are normal reactions to life stresses. With time, and usually, without medical treatment, sadness and grief lift, and people go on with their lives. By contrast, without specialized medical treatment, depression often persists. But with effective treatment, a large majority of people improve significantly. In most instances, MDD is a recurrent, episodic illness. This means that a person who has been depressed once and has recovered is likely to have one or more episodes of depression in the future, often within two to three years. When depression is not treated or is treated inappropriately, it is potentially fatal: nearly one in six people with severe, untreated depression commits suicide. However, seeking help and receiving an accurate diagnosis from a psychiatrist or other health care professional is a crucial and often decisive step toward recovery.

 

MDD is one form of depressive illness or mood disorder. Other forms include bipolar disorder (manic-depressive illness) and dysthymia. In bipolar disorder, episodes of depression alternate with episodes of mania, a condition in which inappropriate or extreme “high” feelings may lead to dangerous, destructive behavior. Dysthymia involves symptoms similar to those of major depressive disorder. The symptoms are milder but longer-lasting, and although they might not be disabling, they prevent a person from feeling good or operating at “full steam.” Occasionally, a person with dysthymia may also have a major depressive disorder, a condition referred to as double depression.

 

According to the World Health Organization (WHO), unipolar depression is one of the leading causes of disability-adjusted life year (DALY) and approximately 350 million people worldwide are said to suffer from this mental disorder. As described in the Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM- V), the hallmark of major depressive disorder is the occurrence of depressed mood (dysphoria) and loss of interest in activities that were rather pleasurable in the past (anhedonia) for a duration of at least two weeks. These symptoms must also be accompanied by at least four of the following manifestations such as changes in appetite or weight, sleep patterns, altered psychomotor activity, feelings of worthlessness or guilt, difficulty concentrating or making decisions, and recurrent thoughts of death or suicidal ideation. Even though there are plenty of drugs developed for the management of depression, one of the challenges in dealing with this disease is that a significant portion of the patients taking antidepressants fails to attain full remission. Some patients also develop treatment-resistant depression in which the patients fail to respond to the available drugs or other therapeutic approaches.

 

Major Depressive Disorder (MDD) Diagnosis and Treatment

The DelveInsight Major Depressive Disorder (MDD) Market Report gives a thorough understanding of major depressive disorder (MDD) by including details of disease definition, symptoms, causes, pathophysiology, and diagnosis.

 

It covers the details of conventional and current medical therapies and diagnoses available in the major depressive disorder (MDD) market to treat the condition. It also provides the country-wise treatment guidelines and algorithms across the United States, Europe, and Japan.

Major Depressive Disorder (MDD) Epidemiology

The major depressive disorder (MDD) epidemiology division provides insights into the historical and current patient pool and the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed incident patient pool, trends, and assumptions.

 

Key Findings

The disease epidemiology covered in the report provides historical and forecasted major depressive disorder (MDD) epidemiology segmented as the 12-month prevalent cases of major depressive disorder, gender-specific cases of major depressive disorder, severity specific cases of major depressive disorder, and relapse/refractory cases of major depressive disorder. The report includes the diagnosed prevalent scenario of major depressive disorder (MDD) symptoms in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.

Country-wise major depressive disorder (MDD) Epidemiology

The epidemiology segment also provides the major depressive disorder (MDD) epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

 

The total 12-month prevalent patient population of MDD in the 7MM countries was over 48 million cases in 2021.

Major depressive disorder (MDD) Drug Chapters

The drug chapter segment of the major depressive disorder (MDD) report encloses the detailed analysis of major depressive disorder (MDD) marketed drugs and late stage (Phase-III, Phase-II/III, Phase-II, and Phase-I/II) pipeline drugs. It also helps understand the major depressive disorder (MDD) clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug, and the latest news and press releases.

 

The evidence-based guideline summarizes recommendations on the use of antidepressants and other drug therapies; psychotherapy, including cognitive behavior therapy; and Electroconvulsive Therapy (ECT). Because many patients with major depressive disorder have co-occurring psychiatric disorders, including substance use disorders, physicians should also consider appropriate treatments for these diagnoses. Patients with mild to moderate depression should be treated with antidepressants or psychotherapy. Combined pharmacotherapy and psychotherapy may be useful in patients with psychosocial or interpersonal problems, intrapsychic conflict, or a co-occurring axis II disorder. ECT can be used in selective patients.

Products detail in the report…

 

Major depressive disorder (MDD) Emerging Drugs

To meet the current demands of the patient pool and to counter the unmet needs of the therapeutic market, drug developers are gradually shifting their attention toward MDD as a possible indication for new targeted therapies.

 

Several companies are working robustly on many new therapies, such as AXS-05 (Axsome Therapeutics), Vraylar (AbbVie), Zuranolone (SAGE Therapeutics), and LY03005 (Luye Pharma). The mid-stage pipeline is crowded, with several potential therapies with the imminent attention of big pharmaceutical companies for this market space.

 

AXS-05 (Axsome Therapeutics), is a novel, oral, patent-protected, investigational NMDA receptor antagonist with multimodal activity under development to treat MDD and other central nervous systems (CNS) disorders. AXS-05 utilizes a proprietary formulation and dose of dextromethorphan and bupropion and Axsome’s metabolic inhibition technology to modulate the delivery of the components. The dextromethorphan component of AXS-05 is an uncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist, also known as a glutamate receptor modulator, which is a novel mechanism of action, meaning it works differently than currently approved therapies for major depressive disorder. The dextromethorphan component of AXS-05 is also a sigma-1 receptor agonist. The bupropion component of AXS-05 serves to increase the bioavailability of dextromethorphan and is a norepinephrine and dopamine reuptake inhibitor.

 

Vraylar (AbbVie) is an oral, once-daily atypical antipsychotic approved for the acute treatment of adult patients with manic or mixed episodes associated with bipolar I disorder, with a recommended dose range of 3–6 mg/day, and for the treatment of schizophrenia in adults, with a recommended dose range of 1.5–6 mg/day.

 

While the mechanism of action of Vraylar in schizophrenia and bipolar I disorder is unknown, the efficacy of VRAYLAR could be mediated through a combination of partial agonist activity at central dopamine D and serotonin 5-HT1A receptors and antagonist activity at serotonin 5-HT2A receptors. Pharmacodynamic studies with cariprazine have shown that it acts as a partial agonist with high binding affinity at dopamine D3, dopamine D2, and serotonin 5-HT1A receptors. Cariprazine demonstrated up to ~eightfold greater in vitro affinity for dopamine D3 vs. D2 receptors. Cariprazine also acts as an antagonist at serotonin 5-HT2B and 5-HT2A receptors with high and moderate binding affinity, respectively, as well as it binds to the histamine H1 receptors. Cariprazine shows lower binding affinity to the serotonin 5-HT2C and 1A- adrenergic receptors and has no appreciable affinity for cholinergic muscarinic receptors. The clinical significance of these in vitro data is unknown. The company has announced the submission of the Supplemental New Drug Application to US FDA for cariprazine (Vraylar) for the adjunctive treatment of MDD.

Products detail in the report…

Major Depressive Disorder (MDD) Market Outlook

The major depressive disorder (MDD) market outlook of the report builds a detailed comprehension of the historical, current, and forecasted major depressive disorder (MDD) market trends by analyzing the impact of current therapies on the market, unmet needs, and demand for better technology.

 

This segment gives a thorough detail of the major depressive disorder (MDD) market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need for the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

 

According to DelveInsight, the major depressive disorder (MDD) market in the 7MM is expected to change in the study period 2019–2032.

 

Key Findings

This section includes a glimpse of the major depressive disorder (MDD) market in the 7MM. The major depressive disorder (MDD) market size in the seven major markets was approximately USD 5,600 million in 2021.

 

The United States: Market Outlook

This section provides the total major depressive disorder (MDD) market size and market size of major depressive disorder (MDD) by therapies in the United States.

 

Depression is a common mental disorder that presents with depressed mood, loss of interest or pleasure in regular activities, decreased energy, feelings of guilt or low self-worth, disturbed sleep or appetite, and poor concentration. Major depressive disorder is the most prevalent and disabling form of depression. In addition to the immediate symptoms of depression, MDD results in poor quality of life and overall decreased productivity and can increase mortality from suicide. Social difficulties including stigma, loss of employment, and marital conflict as a result of depression can also occur. Anxiety Posttraumatic Stress Disorder (PTSD), and substance misuse are common co-occurring conditions that may worsen the existing depression and complicate treatment. Depression is considered to be a largely biological illness but can result from a combination of genetic, biological, environmental, and psychological factors. Trauma, loss of a loved one, a difficult relationship, or any stressful situation may trigger depression, but depression can also occur without an obvious trigger.

 

In cases of MDD severity, if it is determined to be mild to moderate then, the initial treatment is consist of an evidence-based mono-therapy. When the patient prefers psychotherapy, one of the following evidence-based interventions can be offered based on patient preference and availability: Cognitive Behavior Therapy (CBT), Interpersonal Therapy (IPT), Mindfulness-Based Cognitive Therapy (MBCT), Behavioral therapy/behavioral activation (BT/BA), Acceptance and commitment therapy (ACT), and Problem-solving therapy (PST). Further, patients and providers may want to consider that there is some evidence that treatment benefits for CBT and possibly BA may be more enduring than for pharmacotherapy. If the shared decision is made to initiate antidepressant monotherapy, then recommend starting with a Selective serotonin reuptake inhibitor (except fluvoxamine), Serotonin-norepinephrine reuptake inhibitor, mirtazapine, or bupropion. Their efficacies are comparable, and therefore selection should be based on the antidepressant’s safety and side effect profile.

 

The United States accounts for the highest market size of major depressive disorder (MDD) compared to the EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.

 

EU-5 Countries: Market Outlook

The total major depressive disorder (MDD) market size and market size by therapies in Germany, France, Italy, Spain, and the United Kingdom are also mentioned.

 

Japan Market Outlook

The total major depressive disorder (MDD) market size and market size by therapies of major depressive disorder (MDD) in Japan are also mentioned.

Major Depressive Disorder (MDD) Drugs Uptake

This section focuses on the rate of uptake of the potential drugs recently launched or expected to get launched in the market during the study period 2019–2032. The analysis covers major depressive disorder (MDD) market uptake by drugs, patient uptake by therapies, and sales of each drug. 

 

This helps in understanding the drugs with the most rapid uptake, and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on market share and size, which again will be useful in investigating factors important in the market uptake and in making financial and regulatory decisions.

Major Depressive Disorder (MDD) Pipeline Development Activities

The report provides insights into different therapeutic candidates in Phase III, Phase II/III, Phase II, and Phase I/II stages. It also analyses major depressive disorder (MDD)’s key players involved in developing targeted therapeutics.

 

Major players include Axsome Therapeutics, AbbVie, SAGE Therapeutics, and others whose key products are expected to get launched in the US market by 20XX.

 

Pipeline Development Activities

The report covers detailed information on collaborations, acquisitions and mergers, licensing, and patent details for major depressive disorder (MDD) emerging therapies.

KOL Views

To keep up with current market trends, we take KOLs and SMEs’ opinions working in the major depressive disorder (MDD) domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps understand and validate current and emerging therapy treatment patterns or major depressive disorder (MDD) market trends. This will support the clients in potential upcoming novel treatments by identifying the overall scenario of the market and the unmet needs.

Competitive Intelligence Analysis

We perform a Competitive and Market Intelligence analysis of the major depressive disorder (MDD) market using various Competitive Intelligence tools: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies, etc. The inclusion of the analysis entirely depends upon the data availability.

Scope of the Report

  • The report covers the descriptive overview of major depressive disorder (MDD), explaining its causes, signs and symptoms, pathophysiology, and currently available therapies
  • Comprehensive insight is provided into the major depressive disorder (MDD) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for major depressive disorder (MDD) is provided, along with the assessment of new therapies, which will impact the current treatment landscape.
  • A detailed review of the major depressive disorder (MDD) market; historical and forecasted, is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies by understanding trends shaping and driving the global major depressive disorder (MDD) market

Report Highlights

  • In the coming years, the major depressive disorder (MDD) market is set to change due to the rising awareness of the disease and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence major depressive disorder (MDD) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
  • Major players are involved in developing therapies for major depressive disorder (MDD). The launch of emerging therapies will significantly impact the major depressive disorder (MDD) market.
  • A better understanding of disease pathogenesis will also contribute to developing novel therapeutics for major depressive disorder (MDD).
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competitor, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Major Depressive Disorder (MDD) Report Insights

  • Patient Population
  • Therapeutic Approaches
  • Major depressive disorder (MDD) Pipeline Analysis
  • Major depressive disorder (MDD) Market Size and Trends
  • Market Opportunities
  • Impact of upcoming Therapies

Major Depressive Disorder (MDD) Report Key Strengths

  • 11-year Forecast
  • 7MM Coverage
  • Major depressive disorder (MDD) Epidemiology Segmentation
  • Key Competitors
  • Highly Analyzed Market
  • Drugs Uptake

Major Depressive Disorder (MDD) Report Assessment

  • Current Treatment Practices
  • Unmet Needs
  • Pipeline Product Profiles
  • Market Attractiveness

Key Questions

Market Insights:

  • What was the market share (%) distribution, and how would it look in 2032?
  • What would be the major depressive disorder (MDD) total market size and market size by therapies across the 7MM during the forecast period (2019–2032)?
  • What are the key findings pertaining to the market across 7MM, and which country will have the largest major depressive disorder (MDD) market Size during the forecast period (2019–2032)?
  • At what CAGR is the major depressive disorder (MDD) market expected to grow in the 7MM during the forecast period (2019–2032)?
  • What would be the major depressive disorder (MDD) market outlook across the 7MM during the forecast period (2019–2032)?
  • What would be the major depressive disorder (MDD) market growth till 2032 and the resultant market Size in the year 2032?
  • How would the future opportunities affect the market dynamics and subsequent analysis of the associated trends?

 

Epidemiology Insights:

  • What are the disease risk, burden, and unmet needs of major depressive disorder (MDD)?
  • What is the historical patient pool of major depressive disorder (MDD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What would be the forecasted patient pool of major depressive disorder (MDD) in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to major depressive disorder (MDD)?
  • Out of all 7MM countries, which country would have the highest 12-month prevalence of major depressive disorder (MDD) during the forecast period (2019–2032)?
  • At what CAGR is the population expected to grow in the 7MM during the forecast period (2019–2032)?

 

Current Treatment Scenario, Marketed Drugs, and Emerging Therapies:

  • What are the current options for the treatment of the major depressive disorder (MDD)?
  • What are the current treatment guidelines for treating major depressive disorder (MDD) in the US, Europe, and Japan?
  • What are the major depressive disorder (MDD) marketed drugs and their MOA, regulatory milestones, product development activities, advantages, disadvantages, safety, efficacy, etc.?
  • How many companies are developing therapies to treat the major depressive disorder (MDD)?
  • How many therapies are developed by each company for the treatment of the major depressive disorder (MDD)?
  • How many emerging therapies are in the mid-stage and late stages of development to treat the major depressive disorder (MDD)?
  • What are the key collaborations (Industry–Industry, Industry-Academia), Mergers and acquisitions, and licensing activities related to the major depressive disorder (MDD) therapies?
  • What are the recent novel therapies, targets, mechanisms of action, and technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies for major depressive disorder (MDD) and its status?
  • Which key designations have been granted for the emerging therapies for major depressive disorder (MDD)?
  • What are the global historical and forecasted markets for major depressive disorder (MDD)?

Reasons to buy

  • The report will help in developing business strategies by understanding trends shaping and driving the major depressive disorder (MDD) market
  • To understand the future market competition in the major depressive disorder (MDD) market and an Insightful review of the key market drivers and barriers.
  • Organize sales and marketing efforts by identifying the best opportunities for major depressive disorder (MDD) in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan.
  • Identifying strong upcoming players in the market will help devise strategies that will help get ahead of competitors.
  • Organize sales and marketing efforts by identifying the best opportunities for the major depressive disorder (MDD) market.
  • To understand the future market competition in the major depressive disorder (MDD) market.

1. Key Insights

2. Report Introduction

3. Major Depressive Disorder Market Overview at a Glance

3.1. Market Share (%) Distribution of Major Depressive Disorder in 2019

3.2. Market Share (%) Distribution of Major Depressive Disorder in 2032

4. Executive Summary of Major Depressive Disorder

5. Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Types

5.4. Causes

5.5. Pathophysiology of Depression

5.6. Genetic basis of major depressive disorder

5.7. Biomarkers

5.8. Diagnosis and severity

5.8.1. The Diagnostic and Statistical Manual of Mental Disorders (DSM)

5.8.2. DSM-IV-TR Criteria for MDD

5.8.3. DSM-V: Diagnostic Criteria

5.8.4. Differential Diagnosis

5.8.5. DSM-IV-TR Criteria for Major Depressive Disorder

5.8.6. Depression Rating Scale

5.8.7. Montgomery-Åsberg Depression Rating Scale (MADRS)

5.8.8. Depression Rating Scale (DRS)

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total 12-month Prevalent Patient Population of Major Depressive Disorder

6.3. The United States

6.3.1. 12-month Prevalent Cases of Major Depressive Disorder in the US

6.3.2. Gender-specific Prevalence of Major Depressive Disorder in the US

6.3.3. Severity Specific Cases of Major Depressive Disorder in the US

6.3.4. Relapse/Refractory Cases of Major Depressive Disorder in the US

6.4. EU5

6.4.1. Total 12-month Prevalent Cases of MDD in EU-5 Countries

6.4.2. Germany

6.4.3. Gender-specific Prevalence of Major Depressive Disorder in Germany

6.4.4. Severity Specific Cases of Major Depressive Disorder in Germany

6.4.5. Relapse/Refractory Cases of Major Depressive Disorder in Germany

6.4.6. France

6.4.7. Gender-specific Prevalence of Major Depressive Disorder in France

6.4.8. Severity Specific Cases of Major Depressive Disorder in France

6.4.9. Relapse/Refractory Cases of Major Depressive Disorder in France

6.4.10. Italy

6.4.11. Gender-specific Prevalence of Major Depressive Disorder in Italy

6.4.12. Severity Specific Cases of Major Depressive Disorder in Italy

6.4.13. Relapse/Refractory Cases of Major Depressive Disorder in Italy

6.4.14. Spain

6.4.15. Gender-specific Prevalence of Major Depressive Disorder in Spain

6.4.16. Severity Specific Cases of Major Depressive Disorder in Spain

6.4.17. Relapse/Refractory Cases of Major Depressive Disorder in Spain

6.4.18. The United Kingdom

6.4.19. Gender-specific Prevalence of Major Depressive Disorder in the UK

6.4.20. Severity Specific Cases of Major Depressive Disorder in the UK

6.4.21. Relapse/Refractory Cases of Major Depressive Disorder in the UK

6.5. Japan

6.5.1. 12-month Prevalent Cases of Major Depressive Disorder in Japan

6.5.2. Gender-specific Prevalence of Major Depressive Disorder in Japan

6.5.3. Severity Specific Cases of Major Depressive Disorder in Japan

6.5.4. Relapse/Refractory Cases of Major Depressive Disorder in Japan

7. Treatment and Management

7.1. American Psychiatric Association: Guideline on the Treatment of Patients with Major Depressive Disorder

7.2. Major Depressive Disorder Treatment Guidelines in the US and Europe

7.3. Guidelines in Spanish SHN for the Management of Major Depression in Adults

7.4. Major Depressive Disorder Treatment Guidelines in Japan

7.5. Major depressive disorder – Clinical practice review

7.6. Treatment Options for Adults

7.7. Treatment Options for Children and Adolescents

7.8. Treatment Options for Late-Life (Older Adults)

7.9. Algorithm for the Management of Major Depressive Disorder

7.10. Algorithm for the Management of Major Depressive Disorder

8. Organizations contributing towards MDD

9. Patient Journey

10. Case Report

11. Marketed Therapies

11.1. Key cross competition - Marketed Drugs

11.2. Brintellix: Takeda Pharmaceuticals

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Clinical Development

11.2.4. Clinical Trials Information

11.2.5. Safety and Efficacy

11.2.6. Product Profile

11.3. Fetzima: Forest Laboratories

11.3.1. Product Description

11.3.2. Pharmacokinetics

11.3.3. Regulatory Milestones

11.3.4. Clinical Development

11.3.5. Clinical Trials Information

11.3.6. Safety and Efficacy

11.3.7. Product Profile

11.4. Rexulti: Otsuka Pharmaceuticals

11.4.1. Product Description

11.4.2. Pharmacokinetics

11.4.3. Regulatory Milestones

11.4.4. Clinical Development

11.4.5. Clinical Trials Information

11.4.6. Safety and Efficacy

11.4.7. Product Profile

11.5. SPRAVATO (Esketamine): Janssen Research & Development

11.5.1. Product Description

11.5.2. Regulatory Milestones

11.5.3. Clinical Development

11.5.4. Clinical Trials Information

11.5.5. Safety and Efficacy

11.5.6. Product Profile

12. Emerging Therapies

12.1. Key Competitors: Emerging Therapies

12.2. AXS-05: Axsome Therapeutics

12.2.1. Product Description

12.2.2. Regulatory Milestones

12.2.3. Other Development Activities

12.2.4. Clinical Development

12.2.5. Clinical Trials Information

12.2.6. Safety and Efficacy

12.2.7. Product Profile

12.3. Vraylar (Cariprazine): AbbVie

12.3.1. Drug Description

12.3.2. Other development activities

12.3.3. Clinical Development

12.3.4. Clinical Trials Information

12.3.5. Safety and Efficacy

12.3.6. Product Profile

12.4. Zuranolone (SAGE-217/BIIB125): SAGE Therapeutics

12.4.1. Drug Description

12.4.2. Regulatory Milestones

12.4.3. Clinical Development

12.4.4. Clinical Trials Information

12.4.5. Safety and Efficacy

12.4.6. Product Profile

12.5. LY03005: Luye Pharma

12.5.1. Drug Description

12.5.2. Regulatory Milestones

12.5.3. Clinical Development

12.5.4. Clinical Trials Information

12.5.5. Safety and Efficacy

12.5.6. Product Profile

12.6. MIN-202 (Seltorexant): Janssen Pharmaceuticals/Minerva Neurosciences

12.6.1. Drug Description

12.6.2. Other development activities

12.6.3. Clinical Development

12.6.4. Clinical Trials Information

12.6.5. Safety and Efficacy

12.6.6. Product Profile

12.7. REL-1017: Relmada Therapeutics

12.7.1. Product Description

12.7.2. Other Development Activities

12.7.3. Clinical Development

12.7.4. Clinical Trials Information

12.7.5. Safety and Efficacy

12.7.6. Product Profile

12.8. ABV-1504: BioLite Inc.

12.8.1. Drug Description

12.8.2. Regulatory Milestones

12.8.3. Clinical Development

12.8.4. Clinical Trials Information

12.8.5. Safety and Efficacy

12.8.6. Product Profile

12.9. PH10: VistaGen Therapeutics

12.9.1. Drug Description

12.9.2. Regulatory Milestones

12.9.3. Safety and Efficacy

12.9.4. Product Profile

12.10. PRAX-114: Praxis Precision Medicines

12.10.1. Product Description

12.10.2. Other Development Activities

12.10.3. Clinical Development

12.10.4. Clinical Trials Information

12.10.5. Product Profile

12.11. CAPLYTA (Lumateperone): Intra-Cellular Therapies

12.11.1. Product Description

12.11.2. Other Development Activities

12.11.3. Clinical Development

12.11.4. Clinical Trials Information

12.11.5. Product Profile

13. Other Assets

13.1. Key Competitors: Other Assets

13.2. NBI-1065845: Neurocrine Biosciences

13.2.1. Product Description

13.2.2. Other Development Activities

13.2.3. Clinical Development

13.2.4. Clinical trials information

13.2.5. Product Profile

13.3. SP-624: Arrivo Bioventures/Sirstei Pharmaceuticals

13.3.1. Drug Description

13.3.2. Clinical Development

13.3.3. Clinical trials information

13.3.4. Product Profile

13.4. ALTO-300: Alto Neuroscience

13.4.1. Drug Description

13.4.2. Other Development Activities

13.4.3. Clinical Development

13.4.4. Clinical trials information

13.4.5. Product Profile

13.5. CTC-501: Chase Therapeutics

13.5.1. Drug Description

13.5.2. Other development activities

13.5.3. Clinical Development

13.5.4. Clinical Trials Information

13.5.5. Product Profile

13.6. NMRA-140: Neumora Therapeutics, Inc./BlackThorn Therapeutics, Inc.

13.6.1. Drug Description

13.6.2. Other Development Activities

13.6.3. Clinical Development

13.6.4. Clinical Trials Information

13.6.5. Product Profile

13.7. OPC-64005: Otsuka Pharmaceutical Co., Ltd.

13.7.1. Drug Description

13.7.2. Clinical Development

13.7.3. Clinical Trials Information

13.7.4. Product Profile

13.8. Travivo: Fabre-Kramer Pharmaceuticals

13.8.1. Drug Description

13.8.2. Regulatory Milestones

13.8.3. Product Profile

13.9. MIJ821: Novartis

13.9.1. Product Description

13.9.2. Other Development Activities

13.9.3. Clinical Development

13.9.4. Clinical Trials Information

13.9.5. Product Profile

14. Discontinued Therapies

14.1. Pimavanserin: Acadia Pharmaceuticals

14.1.1. Drug Description

14.1.2. Clinical Development

14.1.3. Clinical Trials Information

14.1.4. Product Profile

14.2. Rapastinel: Naurex (Allergan)

14.2.1. Drug Description

14.2.2. Regulatory Milestones

14.2.3. Clinical Development

14.2.4. Clinical Trials Information

14.2.5. Safety and Efficacy

14.2.6. Product Profile

15. Major Depressive Disorder (MDD): 7 Major Market Analysis

15.1. Key Findings

15.2. Market Size of Major Depressive Disorder (MDD) in 7MM

15.3. The United States Market Size

15.3.1. Market Outlook - The US

15.3.2. Total Market Size of Major Depressive Disorder (MDD) in the United States

15.3.3. Market Size of Major Depressive Disorder (MDD) by Therapies

15.4. EU-5 Market

15.4.1. Market Outlook- EU

15.4.2. Total Market Size of Major Depressive Disorder (MDD) in EU-5

15.4.3. Germany

15.4.4. Market Size of Major Depressive Disorder (MDD) by Therapies in Germany

15.4.5. France

15.4.6. Market Size of Major Depressive Disorder (MDD) by Therapies in France

15.4.7. Italy

15.4.8. Market Size of Major Depressive Disorder (MDD) by Therapies in Italy

15.4.9. Spain

15.4.10. Market Size of Major Depressive Disorder (MDD) by Therapies in Spain

15.4.11. The United Kingdom

15.4.12. Market Size of Major Depressive Disorder (MDD) by Therapies in the United Kingdom

15.5. Japan

15.5.1. Market Outlook- Japan

15.5.2. Total Market Size of Major Depressive Disorder (MDD) in Japan

15.5.3. Market Size of Major Depressive Disorder (MDD) by Therapies in Japan

16. SWOT Analysis

17. Unmet Needs

18. Market Access

19. Appendix

19.1. Bibliography

19.2. Report Methodology

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

List of Table

Table 1: Summary of Major Depressive Disorder, Market, Epidemiology, and Key Events (2019–2032)

Table 2: Assessing the severity of depression

Table 3: DSM-IV-TR diagnostic criteria - MDD

Table 4: DSM-IV-TR diagnostic criteria for MDD, Single episode

Table 5: DSM-IV-TR diagnostic criteria for MDD, Recurrent

Table 6: Selected DSM-IV-TR Major Depressive Episode Specifier

Table 7: Major depressive disorder diagnostic criteria according to DSM-V

Table 8: General Diagnostic Criteria of a Depressive episode according to ICD-10

Table 9: Severity Criteria of a Depressive episode according to ICD-10

Table 10: 12-month Prevalent Patient Population of MDD in the 7MM (2019–2032)

Table 11: 12-month Prevalent Cases of Major Depressive Disorder in the US (2019–2032)

Table 12: Gender-specific Prevalence of Major Depressive Disorder in the US (2019–2032)

Table 13: Severity Specific Cases of Major Depressive Disorder in the US (2019–2032)

Table 14: Relapse/Refractory Cases of Major Depressive Disorder in the US (2019–2032)

Table 15: 12-month Prevalent Cases of Major Depressive Disorder in EU-5 (2019–2032)

Table 16: Gender-specific Prevalence of Major Depressive Disorder in Germany (2019–2032)

Table 17: Severity Specific Cases of Major Depressive Disorder in Germany (2019–2032)

Table 18: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2019–2032)

Table 19: Gender-specific Prevalence of Major Depressive Disorder in France (2019–2032)

Table 20: Severity Specific Cases of Major Depressive Disorder in France (2019–2032)

Table 21: Relapse/Refractory Cases of Major Depressive Disorder in France (2019–2032)

Table 22: Gender-specific Prevalence of Major Depressive Disorder in Italy (2019–2032)

Table 23: Severity Specific Cases of Major Depressive Disorder in Italy (2019–2032)

Table 24: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2019–2032)

Table 25: Gender-specific Prevalence of Major Depressive Disorder in Spain (2019–2032)

Table 26: Severity Specific Cases of Major Depressive Disorder in Spain (2019–2032)

Table 27: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2019–2032)

Table 28: Gender-specific Prevalence of Major Depressive Disorder in the UK (2019–2032)

Table 29: Severity Specific Cases of Major Depressive Disorder in the UK (2019–2032)

Table 30: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2019–2032)

Table 31: 12-month Prevalent Cases of Major Depressive Disorder in Japan (2019–2032)

Table 32: Gender-specific Prevalence of Major Depressive Disorder in Japan (2019–2032)

Table 33: Severity Specific Cases of Major Depressive Disorder in Japan (2019–2032)

Table 34: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2019–2032)

Table 35: Organizations contributing towards MDD

Table 36: Key Cross Competition - Marketed Drugs

Table 37: Vortioxetine, Clinical Trial Description, 2022

Table 38: Levomilnacipran ER, Clinical Trial Description, 2022

Table 39: Rexulti, Clinical Trial Description, 2022

Table 40: Esketamine, Clinical Trial Description, 2022

Table 41: Key Competitors: Emerging Therapies

Table 42: AXS-05, Clinical Trial Description, 2022

Table 43: Cariprazine, Clinical Trial Description, 2022

Table 44: SAGE-217, Clinical Trial Description, 2022

Table 45: LY03005, Clinical Trial Description, 2022

Table 46: MIN-202, Clinical Trial Description, 2022

Table 47: REL-1017, Clinical Trial Description, 2022

Table 48: ABV-1504, Clinical Trial Description, 2022

Table 49: PRAX-114, Clinical Trial Description, 2022

Table 50: Lumateperone, Clinical Trial Description, 2022

Table 51: Key Competitors: Other Assets

Table 52: CTC-501, Clinical Trial Description, 2022

Table 53: NMRA-140, Clinical Trial Description, 2022

Table 54: OPC 64005, Clinical Trial Description, 2022

Table 55: MIJ821, Clinical Trial Description, 2022

Table 56: Pimavanserin, Clinical Trial Description, 2022

Table 57: Rapastinel, Clinical Trial Description, 2022

Table 58: Total Market Size of Major Depressive Disorder in the 7MM, in USD Million (2019–2032)

Table 59: The US Market Size of Major Depressive Disorder in USD Million (2019–2032)

Table 60: The US Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Table 61: EU-5 Market Size of Major Depressive Disorder in USD Million (2019–2032)

Table 62: Germany Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Table 63: France Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Table 64: Italy Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Table 65: Spain Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Table 66: The UK Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Table 67: Japan Market Size of Major Depressive Disorder, in USD Million (2019–2032)

Table 68: Japan Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

List of Figures

Figure 1: Structural and Functional Brain Abnormalities in Patients with Major Depressive Disorder

Figure 2: 12-month Prevalent Patient Population of MDD in the 7MM (2019–2032)

Figure 3: 12-month Prevalent Cases of Major Depressive Disorder in the US (2019–2032)

Figure 4: Gender-specific Prevalence of Major Depressive Disorder in the US (2019–2032)

Figure 5: Severity Specific Cases of Major Depressive Disorder in the US (2019–2032)

Figure 6: Relapse/Refractory Cases of Major Depressive Disorder in the US (2019–2032)

Figure 7: 12-month Prevalent Cases of Major Depressive Disorder in EU-5 countries (2019–2032)

Figure 8: Gender-specific Prevalence of Major Depressive Disorder in Germany (2019–2032)

Figure 9: Severity Specific Cases of Major Depressive Disorder in Germany (2019–2032)

Figure 10: Relapse/Refractory Cases of Major Depressive Disorder in Germany (2019–2032)

Figure 11: Gender-specific Prevalence of Major Depressive Disorder in France (2019–2032)

Figure 12: Severity Specific Cases of Major Depressive Disorder in France (2019–2032)

Figure 13: Relapse/Refractory Cases of Major Depressive Disorder in France (2019–2032)

Figure 14: Gender-specific Prevalence of Major Depressive Disorder in Italy (2019–2032)

Figure 15: Severity Specific Cases of Major Depressive Disorder in Italy (2019–2032)

Figure 16: Relapse/Refractory Cases of Major Depressive Disorder in Italy (2019–2032)

Figure 17: Gender-specific Prevalence of Major Depressive Disorder in Spain (2019–2032)

Figure 18: Severity Specific Cases of Major Depressive Disorder in Spain (2019–2032)

Figure 19: Relapse/Refractory Cases of Major Depressive Disorder in Spain (2019–2032)

Figure 20: Gender-specific Prevalence of Major Depressive Disorder in the UK (2019–2032)

Figure 21: Severity Specific Cases of Major Depressive Disorder in the UK (2019–2032)

Figure 22: Relapse/Refractory Cases of Major Depressive Disorder in the UK (2019–2032)

Figure 23: 12-month Prevalent Cases of Major Depressive Disorder in Japan (2019–2032)

Figure 24: Gender-specific Prevalence of Major Depressive Disorder in Japan (2019–2032)

Figure 25: Severity Specific Cases of Major Depressive Disorder in Japan (2019–2032)

Figure 26: Relapse/Refractory Cases of Major Depressive Disorder in Japan (2019–2032)

Figure 27: Basic Principles of Depression Treatment in American and European Guidelines

Figure 28: Total Market Size of Major Depressive Disorder, in USD Million (2019–2032)

Figure 29: The US Market size of Major Depressive Disorder, in USD million (2019–2032)

Figure 30: The US Market Size of Major Depressive Disorder by Therapies (2019–2032)

Figure 31: EU-5 Market Size of Major Depressive Disorder, in USD Million (2019–2032)

Figure 32: Germany Market Size of Major Depressive Disorder by Therapies (2019–2032)

Figure 33: France Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Figure 34: Italy Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Figure 35: Spain Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Figure 36: The UK Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Figure 37: Japan Market Size of Major Depressive Disorder, in USD Million (2019–2032)

Figure 38: Japan Market Size of Major Depressive Disorder by Therapies, in USD Million (2019–2032)

Takeda Pharmaceuticals
Forest Laboratories
Otsuka Pharmaceuticals
Janssen Research & Development
Axsome Therapeutics
AbbVie
SAGE Therapeutics
Minerva Neurosciences
Luye Pharma
Relmada Therapeutics
BioLite Inc.
VistaGen Therapeutics
Praxis Precision Medicines
Intra-Cellular Therapies
Neurocrine Biosciences
Arrivo Bioventures
Sirstei Pharmaceuticals
Alto Neuroscience
Chase Therapeutics
Neumora Therapeutics, Inc.
BlackThorn Therapeutics, Inc.
Otsuka Pharmaceutical Co., Ltd.
Fabre-Kramer Pharmaceuticals
Novartis

 

Forward to Friend

Need A Quote